secwatch.observer — SEC 8-K summary
======================================

Issuer:     HARROW, INC. (HROW)
CIK:        0001360214
Form:       8-K/A
Filed at:   2025-10-01T23:59:59+00:00
Accession:  0001493152-25-016473
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harrow to acquire Melt Pharmaceuticals for $0.50/share; already owns 45%
------------------------------------------------------------------------

- Harrow will pay $0.50 per share of Melt Common Stock for the remaining ~55% it does not already own.
- Melt is a clinical-stage company developing MELT-300 for procedural sedation in cataract surgery.
- Transaction approved by special committees of both boards, each receiving fairness opinions.
- Harrow and Melt entered a Milestone Payment Agreement tied to regulatory and sales milestones.
- Merger Sub will merge with and into Melt; Melt will survive as wholly owned subsidiary of Harrow.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1360214/000149315225016473/0001493152-25-016473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1360214/000149315225016473/form8-ka.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-016473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer